Economic and developmental considerations for pharmacogenomic technology

PharmacoEconomics

Volumn 24, Issue 4, 2006, Pages 335-343

  Vernon, John A ^a,b   Johnson, Scott J ^c   Hughen, W Keener ^d   Trujillo, Antonio ^e  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b National Bureau for Economic Research (NBER)   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COMMERCIAL PHENOMENA; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG INDUSTRY; DRUG MARKETING; DRUG RESPONSE; GENE EXPRESSION; GENE TECHNOLOGY; HUMAN; MARKER GENE; MARKET; MATHEMATICAL MODEL; PHARMACOGENOMICS; POPULATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; REVIEW; SCIENCE;

COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DECISION SUPPORT TECHNIQUES; DRUG INDUSTRY; GENETIC SCREENING; MODELS, ECONOMIC; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645826772     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624040-00004     Document Type: Review

References (11)

1. Bhandari M, Garg R, Glassman R, et al. The pharmacogenomics challenge: the only option is how and when you participate. In Vivo 1999; 17 (3): 36-41
2. Med Ad News, May 2005 from Pharmlive.com special reports [online]. Available from URL: http://www.pharmalive.comspecial_reports-sample.cfmreportID= 191 [Accessed 2005 Jul 19]
3. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989; 262 (20): 2879-86
4. Sloan F, editor. Valuing health care. 2nd ed. Cambridge: Cambridge University Press, 1995
5. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1997
6. Jommi C. Pharmaceutical policy and organisation of the regulatory authorities in the main EU countries. Cergas: Egea Publishing, 2001
7. Gosling H. European pharmacoeconomics: the fourth hurdle, global pharmaceutical reports. New York: SMi Publishing, 2000
8. Atkinson T. The global parallel trade outlook 2001-2006: a country-by-country analysis. London: REUTERS Business Insights, 2001
9. Danzon P, Towse A. The economics of gene therapy and pharmacogenetics. Value Health 2002; 5 (1): 5-13
10. Vernon JA, Hughen WK, Johnson SJ. Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/no-go decisions. Health Care Manag Sci 2005; 8 (2): 167-79
11. Miller P. Role of pharmacoeconomic analysis in R&D decision making: when, where, how? Pharmacoeconomics 2005; 23 (1): 1-12